亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma

医学 异维甲酸 卡铂 内科学 肿瘤科 髓母细胞瘤 化疗 癌症研究 皮肤病科 顺铂 痤疮
作者
Sarah Leary,Roger J. Packer,Yimei Li,Catherine A. Billups,Kyle Smith,Alok Jaju,Linda Heier,Peter C. Burger,Karin S. Walsh,Yuanyuan Han,Leanne Embry,Jennifer Hadley,Rahul Kumar,Jeff M. Michalski,Eugene Hwang,Amar Gajjar,Ian F. Pollack,Maryam Fouladi,Paul A. Northcott,James M. Olson
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (9): 1313-1313 被引量:156
标识
DOI:10.1001/jamaoncol.2021.2224
摘要

IMPORTANCE: Brain tumors are the leading cause of disease-related death in children. Medulloblastoma is the most common malignant embryonal brain tumor, and strategies to increase survival are needed. OBJECTIVE: To evaluate therapy intensification with carboplatin as a radiosensitizer and isotretinoin as a proapoptotic agent in children with high-risk medulloblastoma in a randomized clinical trial and, with a correlative biology study, facilitate planned subgroup analysis according to World Health Organization consensus molecular subgroups of medulloblastoma. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical phase 3 trial was conducted from March 2007 to September 2018. Analysis was completed in September 2020. Patients aged 3 to 21 years with newly diagnosed high-risk medulloblastoma from Children's Oncology Group institutions within the US, Canada, Australia, and New Zealand were included. High-risk features included metastasis, residual disease, or diffuse anaplasia. INTERVENTIONS: Patients were randomized to receive 36-Gy craniospinal radiation therapy and weekly vincristine with or without daily carboplatin followed by 6 cycles of maintenance chemotherapy with cisplatin, cyclophosphamide, and vincristine with or without 12 cycles of isotretinoin during and following maintenance. MAIN OUTCOMES AND MEASURES: The primary clinical trial end point was event-free survival, using the log-rank test to compare arms. The primary biology study end point was molecular subgroup classification by DNA methylation array. RESULTS: Of 294 patients with medulloblastoma, 261 were evaluable after central radiologic and pathologic review; median age, 8.6 years (range, 3.3-21.2); 183 (70%) male; 189 (72%) with metastatic disease; 58 (22%) with diffuse anaplasia; and 14 (5%) with greater than 1.5-cm2 residual disease. For all participants, the 5-year event-free survival was 62.9% (95% CI, 55.6%-70.2%) and overall survival was 73.4% (95% CI, 66.7%-80.1%). Isotretinoin randomization was closed early owing to futility. Five-year event-free survival was 66.4% (95% CI, 56.4%-76.4%) with carboplatin vs 59.2% (95% CI, 48.8%-69.6%) without carboplatin (P = .11), with the effect exclusively observed in group 3 subgroup patients: 73.2% (95% CI, 56.9%-89.5%) with carboplatin vs 53.7% (95% CI, 35.3%-72.1%) without (P = .047). Five-year overall survival differed by molecular subgroup (P = .006): WNT pathway activated, 100% (95% CI, 100%-100%); SHH pathway activated, 53.6% (95% CI, 33.0%-74.2%); group 3, 73.7% (95% CI, 61.9%-85.5%); and group 4, 76.9% (95% CI, 67.3%-86.5%). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, therapy intensification with carboplatin improved event-free survival by 19% at 5 years for children with high-risk group 3 medulloblastoma. These findings further support the value of an integrated clinical and molecular risk stratification for medulloblastoma. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00392327.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
欢呼爆米花完成签到 ,获得积分10
6秒前
lujibaqi完成签到 ,获得积分20
7秒前
凶狠的草莓完成签到,获得积分10
9秒前
12秒前
ding的应助被brinty采纳,获得10
14秒前
感性的又菡完成签到,获得积分10
14秒前
lujibaqi关注了科研通微信公众号
17秒前
soilman发布了新的文献求助10
18秒前
vicissitude发布了新的文献求助10
18秒前
22秒前
33秒前
33秒前
37秒前
37秒前
慕青的应助被vicissitude采纳,获得10
37秒前
brinty发布了新的文献求助10
38秒前
王航完成签到,获得积分20
39秒前
41秒前
张晓龙发布了新的文献求助10
41秒前
王航发布了新的文献求助10
43秒前
毒药完成签到 ,获得积分10
43秒前
JamesPei的应助被lujibaqi采纳,获得10
46秒前
vicissitude完成签到,获得积分10
46秒前
想喝三碗粥完成签到,获得积分10
49秒前
危机的白凡完成签到,获得积分10
1分钟前
受伤若男完成签到,获得积分10
1分钟前
李健的小迷弟的应助被sxh采纳,获得30
1分钟前
KinoFreeze完成签到 ,获得积分0
1分钟前
1分钟前
1分钟前
水煮电吹风的应助被Samuel采纳,获得10
1分钟前
1分钟前
369ninja的应助被科研通管家采纳,获得10
1分钟前
脑洞疼的应助被科研通管家采纳,获得10
1分钟前
1分钟前
brinty完成签到,获得积分10
1分钟前
Akim的应助被soilman采纳,获得10
1分钟前
1分钟前
忧心的曼凝的应助被Samuel采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185091
求助须知:如何正确求助?哪些是违规求助? 9574009
关于积分的说明 21833941
捐赠科研通 7782532
什么是DOI,文献DOI怎么找? 3434500
关于科研通互助平台的介绍 2558701
邀请新用户注册赠送积分活动 2481201